End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.2 CNY | -1.44% | +1.96% | -16.78% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.78% | 4.51B | C+ | ||
+43.33% | 6.34B | B- | ||
-6.93% | 3.29B | B- | ||
+3.89% | 3.2B | C | ||
-0.88% | 2.59B | - | D+ | |
+46.64% | 2.09B | - | ||
-5.34% | 1.76B | - | - | |
+1.60% | 1.7B | - | - | |
-7.31% | 1.62B | C- | ||
+47.94% | 1.55B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002603 Stock
- Ratings Shijiazhuang Yiling Pharmaceutical Co., Ltd.